Contraception
Volume 64, Issue 4 , Pages 217-222 , October 2001

Impact of oral contraceptive use on APC-resistance: a prospective, randomized clinical trial with three low-dose preparations

  • J. Endrikat

      Affiliations

    • Corresponding Author InformationCorresponding author. Tel.: +49-304681-7864; fax: +49-304681-8191
    • Schering AG, Müllerstr. 178, D-13342 Berlin, Germany
  • ,
  • M. Noah

      Affiliations

    • Dade Behring Marburg GmbH, Postfach 1149, D-35001 Marburg, Germany
  • ,
  • C. Gerlinger

      Affiliations

    • Schering AG, Müllerstr. 178, D-13342 Berlin, Germany
  • ,
  • R. Bannemerschult

      Affiliations

    • Schering AG, Müllerstr. 178, D-13342 Berlin, Germany
  • ,
  • W. Junge

      Affiliations

    • Laboratorium für Klin. Forschung, Lise-Meitner-Str. 25-29, D-24223 Raisdorf/Kiel, Germany
  • ,
  • A. Ruebig

      Affiliations

    • Schering AG, Müllerstr. 178, D-13342 Berlin, Germany
  • ,
  • W. Schmidt

      Affiliations

    • Universitätskliniken des Saarlandes, Frauenklinik und Poliklinik, D-66421 Homburg/Saar, Germany
  • ,
  • B. Düsterberg

      Affiliations

    • Schering AG, Müllerstr. 178, D-13342 Berlin, Germany

References 

  1. Bertina RM, Koeleman BPC, Koster T, et al.  Mutation in blood coagulation factor V associated with resistance to activated protein C. Nature. 1994;369:64–67
  2. Vandenbroucke JP, Koster T, Briët E, et al.  Increased risk of venous thrombosis in oral contraceptive users who are carriers of factor V Leiden mutation. Lancet. 1994;344:1453–1457
  3. Jespersen J. Plasma resistance to activated protein C (an important link between venous thromboembolism, and combined oral contraceptives, a short review). Eur J Contracept Reprod Health Care. 1996;1:3–11
  4. Rosen SB, Sturk A. Activated protein C resistance—a major risk factor for thrombosis. Eur J Clin Chem Clin Biochem. 1997;35(Suppl 7):501–516
  5. Walker ID. Factor V Leiden (should all women be screened prior to commencing the contraceptive pill?). Blood Rev. 1999;13(Suppl 1):8–13
  6. Cumming AM, Tait RC, Fildes S, et al.  Development of resistance to activated protein C during pregnancy. Int J Hematol. 1995;90:725–727
  7. Osterud B, Robertsen R, Åsvang GB, Thijssen F. Resistance to activated protein C is reduced in women using oral contraceptives. Blood Coagul Fibrinol. 1994;5:853–854
  8. Oliveri O, Friso S, Manzato F, et al.  Resistance to activated protein C in healthy women taking oral contraceptives. Brit J Hematol. 1995;9:465–470
  9. Currers J, Thomassen CL, Nicolaes GA, et al.  Acquired APC-resistance and oral contraceptives (differences between two functional tests). Brit J Hematol. 1999;105:88–94
  10. Datt F, Hafner G, Erbes H, et al.  ProC Global (the first functional screening assay for the complete protein C pathway). Clin Chem. 1997;43:1719–1723
  11. Kraus M, Noah M, Fickenscher K. The PCAT—a simple screening assay for assessing the functionality of the protein C anticoagulant pathway. Thrombosis Res. 1995;79:217–222
  12. Comp PC. Thrombophilic mechanisms of OCs. Int J Fertil Women S Med. 1997;42(Suppl 1):170–176
  13. Girolami A, Simioni P, Girolami B, Radossi P. Homozygous patients with APC-resistance may remain paucisymptomatic or asymptomatic during oral contraception. Blood Coagul Fibrinolysis. 1996;7:590–594
  14. Spannagl M, Dick A, Assmann A, Heinemann L, Schramm W. Resistance to activated protein C in women using oral contraceptives. Semin Thromb Hemost. 1998;24(Suppl 5):423–430
  15. Winkler UH. Activated protein C resistance, and deficiencies of antithrombin III, protein C or protein S, and the risk of thromboembolic disease in users of oral contraceptives. Eur J Contracept Reprod Health Care. 1998;3(Suppl 2):65–74
  16. Winkler UH. Blood coagulation, and oral contraceptives. Contraception. 1998;57:203–209
  17. Palareti G, Legnani C, Frascaro M, et al.  Screening for activated protein C resistance before oral contraceptive treatment (a pilot study). Contraception. 1999;59:292–299

PII: S0010-7824(01)00253-0

Contraception
Volume 64, Issue 4 , Pages 217-222 , October 2001